CP 47,497

CP 47,497
Legal status
Legal status
Identifiers
  • 2-[(1S,3R)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H34O2
Molar mass318.501 g·mol−1
3D model (JSmol)
  • (1S,3R): CCCCCCC(C)(C)c1ccc(c(c1)O)[C@H]2CCC[C@H](C2)O

  • (1R,3S): CCCCCCC(C)(C)c1ccc(c(c1)O)[C@@H]2CCC[C@@H](C2)O
  • (1S,3R): InChI=1S/C21H34O2/c1-4-5-6-7-13-21(2,3)17-11-12-19(20(23)15-17)16-9-8-10-18(22)14-16/h11-12,15-16,18,22-23H,4-10,13-14H2,1-3H3/t16-,18+/m0/s1
  • Key:ZWWRREXSUJTKNN-FUHWJXTLSA-N

  • (1R,3S): InChI=1S/C21H34O2/c1-4-5-6-7-13-21(2,3)17-11-12-19(20(23)15-17)16-9-8-10-18(22)14-16/h11-12,15-16,18,22-23H,4-10,13-14H2,1-3H3/t16-,18+/m1/s1
  • Key:ZWWRREXSUJTKNN-AEFFLSMTSA-N

CP 47,497 or (C7)-CP 47,497 is a cannabinoid receptor agonist drug, developed by Pfizer in the 1980s.[1] It has analgesic effects and is used in scientific research. It is a potent CB1 agonist with a Kd of 2.1 nM.[2][3][4]

  1. ^ Weissman A, Milne GM, Melvin LS (November 1982). "Cannabimimetic activity from CP-47,497, a derivative of 3-phenylcyclohexanol". The Journal of Pharmacology and Experimental Therapeutics. 223 (2): 516–23. PMID 6290642.
  2. ^ Shim JY, Welsh WJ, Howlett AC (2003). "Homology model of the CB1 cannabinoid receptor: sites critical for nonclassical cannabinoid agonist interaction". Biopolymers. 71 (2): 169–89. doi:10.1002/bip.10424. PMID 12767117. S2CID 7909397.
  3. ^ Roger Pertwee. Cannabinoids. Handbook of Experimental Pharmacology Volume 168. Springer. ISBN 3-540-22565-X
  4. ^ Little PJ, Compton DR, Johnson MR, Melvin LS, Martin BR (December 1988). "Pharmacology and stereoselectivity of structurally novel cannabinoids in mice". The Journal of Pharmacology and Experimental Therapeutics. 247 (3): 1046–51. PMID 2849657.

© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search